For the selection of drug candidates that specifically inhibited the growth of CD133 (+) TICs, we utilized Huh7 cells as a surrogate, which is a human HCC cell line with approximately 50–60% of cells constitutively expressing CD133 (Figure 1E, bottom left). The gene discussed is PROM1; the disease is hepatocellular carcinoma.